FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109601043> ?p ?o ?g. }

• W2109601043 endingPage "1560" @default.
• W2109601043 startingPage "1559" @default.
• W2109601043 abstract "In the January issue of Annals of Oncology, von Minckwitz and colleagues reported their pilot study of preoperative chemotherapy with the TAC regimen (docetaxel, adriamycin, and cyclophosphamide) adapted by clinical evaluation after two cycles [1.von Minckwitz G. Blohmer J.U. Raab G. et al.In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GERPATRIO pilot study.Ann Oncol. 2005; 16: 56-63Abstract Full Text Full Text PDF PubMed Scopus (167) Google Scholar]. The patients with at least partial response received four additional cycles of TAC although the others were randomised to either TAC or the combination of vinorelbine and capecitabine (NX). A high complete pathological response rate (pCR) of 22.9% was obtained in responders to the first two cycles. Nevertheless, this study deserves a number of additional comments. The first point is the method of evaluation of response since there is also a demonstration of the poor correlation between palpation and echography. A second point is the recruitment which did not favour chemosensitivity given the minority of patients (36%) with histologic grade III, or with hormone negative status (32%). More than 25% of the patients were older than 60 years who would probably have poorly tolerated such a heavy regimen. We do not agree with the relatively optimistic presentation of the toxicity which included febrile neutropenia in 13.5% of the patients under TAC and grade III/IV neutropenia in 34% under NX. It must be taken into account that the patients have been particularly well followed in the setting of a clinical trial conducted in university hospitals. Moreover, the patients have been inevitably selected. These phenomenon are particularly well illustrated by the extremely low rate of manageable toxicity such as nausea, edema, or hand-foot syndrome. The administration of TAC or NX might be more problematic in general practice. Regarding the results, the low pCR after NX indicates the inefficacy of this regimen after failure of TAC, which is conceptually comprehensible and should lead to its disqualification. In fact, the key-point is the choice of TAC since a high proportion of the tumours is resistant to at least one of the three drugs while all patients are exposed to toxicity. There is a contradiction between in vivo adaptation and the use of a wide-spectrum regimen with no possibility of second-line therapy. In the Aberdeen study, the patients who were refractory to the anthracyclin-based regimen exceptionally took benefit from docetaxel [2.Smith I.C. Heys S.D. Hutcheon A.W. et al.Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.J Clin Oncol. 2002; 20: 1456-1466Crossref PubMed Scopus (682) Google Scholar]. In fact, all these studies indicates that there is a fraction of clearly refractory patients. Even an intensified regimen did not show improvement in the results. In a study of 57 patients with stage III disease receiving three cycles of epirubicin, 100 mg/m2, and cyclophosphamide, 1200 mg/m2 every two weeks, the pCR was only 3.5% [3.Fisher B. Anderson S. DeCillis A. et al.Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.J Clin Oncol. 1998; 17: 3374-3388Crossref Scopus (205) Google Scholar]. A phase III study comparing EC (epirubicin, 120 mg/m2 and cyclophosphamide, 830 mg/m2 every 2 weeks) with FEC (5-fluorouracil, epirubicin, 60 mg/m2 D1, and cyclophosphamide, 75 mg/m2/day D1-D14, one cycle every 4 weeks), resulted in equivalent pCR [4.Therasse P. Mauriac L. Welnicka-Jasliewicz M. et al.Final results of a randomized phase III study comparing cyclophosphamide, epirubicin, and fluorouracil with a dose intensified epirubicin and cyclophosphamide + filgrastim as neo-adjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.J Clin Oncol. 2003; 21: 843-850Crossref PubMed Scopus (187) Google Scholar]. In conclusion, a sequential treatment including a taxane in responders seems an appropriate approach in hormone negative receptor patients with probably no loss of chance but less toxicity. Unfortunately, no alternative approach is proposed to the other patients while hormonal therapy, trastuzumab, or even irradiation might be considered." @default.
• W2109601043 created "2016-06-24" @default.
• W2109601043 creator A5029870261 @default.
• W2109601043 date "2005-09-01" @default.
• W2109601043 modified "2023-09-30" @default.
• W2109601043 title "In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer" @default.
• W2109601043 cites W2109079833 @default.
• W2109601043 cites W2138734774 @default.
• W2109601043 cites W2164409215 @default.
• W2109601043 cites W2167779518 @default.
• W2109601043 doi "https://doi.org/10.1093/annonc/mdi287" @default.
• W2109601043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16079161" @default.
• W2109601043 hasPublicationYear "2005" @default.
• W2109601043 type Work @default.
• W2109601043 sameAs 2109601043 @default.
• W2109601043 citedByCount "0" @default.
• W2109601043 crossrefType "journal-article" @default.
• W2109601043 hasAuthorship W2109601043A5029870261 @default.
• W2109601043 hasBestOaLocation W21096010431 @default.
• W2109601043 hasConcept C121608353 @default.
• W2109601043 hasConcept C126322002 @default.
• W2109601043 hasConcept C141071460 @default.
• W2109601043 hasConcept C143998085 @default.
• W2109601043 hasConcept C146357865 @default.
• W2109601043 hasConcept C151730666 @default.
• W2109601043 hasConcept C2776694085 @default.
• W2109601043 hasConcept C2776755627 @default.
• W2109601043 hasConcept C2777063308 @default.
• W2109601043 hasConcept C2777909004 @default.
• W2109601043 hasConcept C2778239845 @default.
• W2109601043 hasConcept C2778336483 @default.
• W2109601043 hasConcept C2778850193 @default.
• W2109601043 hasConcept C2780350996 @default.
• W2109601043 hasConcept C2781190966 @default.
• W2109601043 hasConcept C2781413609 @default.
• W2109601043 hasConcept C526805850 @default.
• W2109601043 hasConcept C530470458 @default.
• W2109601043 hasConcept C71924100 @default.
• W2109601043 hasConcept C86803240 @default.
• W2109601043 hasConceptScore W2109601043C121608353 @default.
• W2109601043 hasConceptScore W2109601043C126322002 @default.
• W2109601043 hasConceptScore W2109601043C141071460 @default.
• W2109601043 hasConceptScore W2109601043C143998085 @default.
• W2109601043 hasConceptScore W2109601043C146357865 @default.
• W2109601043 hasConceptScore W2109601043C151730666 @default.
• W2109601043 hasConceptScore W2109601043C2776694085 @default.
• W2109601043 hasConceptScore W2109601043C2776755627 @default.
• W2109601043 hasConceptScore W2109601043C2777063308 @default.
• W2109601043 hasConceptScore W2109601043C2777909004 @default.
• W2109601043 hasConceptScore W2109601043C2778239845 @default.
• W2109601043 hasConceptScore W2109601043C2778336483 @default.
• W2109601043 hasConceptScore W2109601043C2778850193 @default.
• W2109601043 hasConceptScore W2109601043C2780350996 @default.
• W2109601043 hasConceptScore W2109601043C2781190966 @default.
• W2109601043 hasConceptScore W2109601043C2781413609 @default.
• W2109601043 hasConceptScore W2109601043C526805850 @default.
• W2109601043 hasConceptScore W2109601043C530470458 @default.
• W2109601043 hasConceptScore W2109601043C71924100 @default.
• W2109601043 hasConceptScore W2109601043C86803240 @default.
• W2109601043 hasIssue "9" @default.
• W2109601043 hasLocation W21096010431 @default.
• W2109601043 hasLocation W21096010432 @default.
• W2109601043 hasOpenAccess W2109601043 @default.
• W2109601043 hasPrimaryLocation W21096010431 @default.
• W2109601043 hasRelatedWork W1858470829 @default.
• W2109601043 hasRelatedWork W1988166003 @default.
• W2109601043 hasRelatedWork W1998091677 @default.
• W2109601043 hasRelatedWork W2003291927 @default.
• W2109601043 hasRelatedWork W2029487834 @default.
• W2109601043 hasRelatedWork W2142770096 @default.
• W2109601043 hasRelatedWork W2388730008 @default.
• W2109601043 hasRelatedWork W3000675521 @default.
• W2109601043 hasRelatedWork W4255677651 @default.
• W2109601043 hasRelatedWork W2739364109 @default.
• W2109601043 hasVolume "16" @default.
• W2109601043 isParatext "false" @default.
• W2109601043 isRetracted "false" @default.
• W2109601043 magId "2109601043" @default.
• W2109601043 workType "article" @default.